INTERPACE BIOSCIENCES, INC. (IDXG) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US46062X3035

Price
5.72 USD
Market cap
31.68 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

INTERPACE BIOSCIENCES, INC. financials

Fiscal year2025
Revenue38.73 m USD
Gross profit24.13 m USD
Operating income4.08 m USD
EBIT3.37 m USD
Net income24.58 m USD
Diluted EPS – continuing operations0.89 USD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About INTERPACE BIOSCIENCES, INC.

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.